Zusammenfassung
Mit zunehmender Verbreitung von kombinierten PET/CT-Geräten hat die multimodale nuklearmedizinisch-radiologische
Bildgebung in den letzten Jahren Einzug in die klinische Routine gefunden. Speziell
bei pädiatrischen und pädiatrisch-onkologischen Fragestellungen stellt jedoch die
MRT die Methode der Wahl zur morphologischen Bildgebung dar. Im Rahmen dieser Übersicht
werden die notwendigen Komponenten für die multimodale PET/MRT-Bildgebung, die Indikationen
für pädiatrische MRT-Untersuchungen, Strategien der Bildanalyse und Bildpräsentation
sowie die diagnostischen Erwartungen an die kombinierte Diagnostik und deren Limitationen
vorgestellt und diskutiert.
Abstract
With increasing use of combined PET/CT scanners in the last few years, multimodality
imaging (Nuclear Medicine/Radiology) found its way into clinical routine diagnostics.
Especially in pediatric oncology, however, MRI is the modality of choice for morphological
imaging. In this overview, necessary components for multimodality imaging, indications
for pediatric MRI, strategies for image analysis and image presentation, and diagnostic
goals and limitations of combined PET/MR-imaging are demonstrated and discussed.
Schlüsselwörter
multimodale Bildgebung - PET/MRT - Bildfusion - pädiatrische Onkologie
Key words
multimodality imaging - PET/MRI - image fusion - pediatric oncology
Literatur
- 1
Connolly L P, Drubach L A, Ted Treves S.
Applications of nuclear medicine in pediatric oncology.
Clin Nucl Med.
2002;
27
117-125
- 2
Schmidt G P, Baur-Melnyk A, Tiling R, Hahn K, Reiser M F, Schoenberg S O.
Comparison of high resolution whole-body MRI using parallel imaging and PET-CT. First
experiences with a 32-channel MRI system.
Radiologe.
2004;
44
889-898
- 3
Bloem J L, van der Woude H J, Geirnaerdt M, Hogendoorn P C, Taminiau A H, Hermans J.
Does magnetic resonance imaging make a difference for patients with musculoskeletal
sarcoma?.
Br J Radiol.
1997;
70
327-337
- 4
Bredella M A, Caputo G R, Steinbach L S.
Value of FDG positron emission tomography in conjunction with MR imaging for evaluating
therapy response in patients with musculoskeletal sarcomas.
AJR Am J Roentgenol.
2002;
179
1145-1150
- 5
Antoch G, Vogt F M, Bockisch A, Ruehm S G.
Whole-body tumor staging: MRI or FDG-PET/CT?.
Radiologe.
2004;
44
882-888
- 6
Gaa J, Rummeny E J, Seemann M D.
Whole-body imaging with PET/MRI.
Eur J Med Res.
2004;
9
309-312
- 7
Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S, Schmid I, Hahn K.
Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the
diagnosis of pediatric neuroblastoma.
AJR Am J Roentgenol.
2003;
181
1115-1124
- 8
Czernin J.
Clinical applications of FDG-PET in oncology.
Acta Med Austriaca.
2002;
29
162-170
- 9
Alyafei S, Inoue T, Zhang H, Ahmed K, Oriuchi N, Sato N, Suzuki H, Endo K.
Image fusion system using PACS for MRI, CT, and PET images.
Clin Positron Imaging.
1999;
2
137-143
- 10
Hutton B F, Braun M.
Software for image registration: algorithms, accuracy, efficacy.
Semin Nucl Med.
2003;
33
180-192
- 11
Slomka P J.
Software approach to merging molecular with anatomic information.
J Nucl Med.
2004;
45 (Suppl 1)
36S-45S
- 12
Pelizzari C A, Chen G T, Spelbring D R, Weichselbaum R R, Chen C T.
Accurate three-dimensional registration of CT, PET, and/or MR images of the brain.
J Comput Assist Tomogr.
1989;
13
20-26
- 13
Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P.
Multimodality image registration by maximization of mutual information.
IEEE Trans Med Imaging.
1997;
16
187-198
- 14
Wells 3rd
W M, Viola P, Atsumi H, Nakajima S, Kikinis R.
Multi-modal volume registration by maximization of mutual information.
Med Image Anal.
1996;
1
35-51
- 15
Skalski J, Wahl R L, Meyer C R.
Comparison of mutual information-based warping accuracy for fusing body CT and PET
by 2 methods: CT mapped onto PET emission scan versus CT mapped onto PET transmission
scan.
J Nucl Med.
2002;
43
1184-1187
- 16
Cohade C, Osman M, Marshall L N, Wahl R N.
PET-CT: accuracy of PET and CT spatial registration of lung lesions.
Eur J Nucl Med Mol Imaging.
2003;
30
721-726
Epub 2003 Mar 1
- 17
Stokking R, Zubal I G, Viergever M A.
Display of fused images: methods, interpretation, and diagnostic improvements.
Semin Nucl Med.
2003;
33
219-227
- 18
Anderson H, Price P.
What does positron emission tomography offer oncology?.
Eur J Cancer.
2000;
36
2028-2035
- 19
Bar-Shalom R, Valdivia A Y, Blaufox M D.
PET imaging in oncology.
Semin Nucl Med.
2000;
30
150-185
- 20
Czech N, Brenner W, Kampen W U, Henze E.
[Diagnostic value of positron emission tomography (PET) in clinical oncology].
Dtsch Med Wochenschr.
2000;
125
565-567
- 21
Delbeke D, Martin W H.
Positron emission tomography imaging in oncology.
Radiol Clin North Am.
2001;
39
883-917
- 22
Mankoff D A, Bellon J R.
Positron-emission tomographic imaging of cancer: glucose metabolism and beyond.
Semin Radiat Oncol.
2001;
11
16-27
- 23
Scott A M.
Current status of positron emission tomography in oncology.
Intern Med J.
2001;
31
27-36
- 24
Brisse H, Ollivier L, Edeline V, Pacquement H, Michon J, Glorion C, Neuenschwander S.
Imaging of malignant tumours of the long bones in children: monitoring response to
neoadjuvant chemotherapy and preoperative assessment.
Pediatr Radiol.
2004;
34
595-605
, Epub 2004 Apr 22
- 25
Daldrup-Link H E, Franzius C, Link T M, Laukamp D, Sciuk J, Jurgens H, Schober O,
Rummeny E J.
Whole-body MR imaging for detection of bone metastases in children and young adults:
comparison with skeletal scintigraphy and FDG PET.
AJR Am J Roentgenol.
2001;
177
229-236
- 26
Franzius C, Daldrup-Link H E, Wagner-Bohn A, Sciuk J, Heindel W L, Jurgens H, Schober O.
FDG-PET for detection of recurrences from malignant primary bone tumors: comparison
with conventional imaging.
Ann Oncol.
2002;
13
157-160
- 27
Hawkins D S, Rajendran J G, Conrad 3rd
E U, Bruckner J D, Eary J F.
Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose
positron emission tomography.
Cancer.
2002;
94
3277-3284
- 28
Hudson M M, Krasin M J, Kaste S C.
PET imaging in pediatric Hodgkin's lymphoma.
Pediatr Radiol.
2004;
34
190-198
, Epub 2004 Jan 27
- 29
Montravers F, McNamara D, Landman-Parker J, Grahek D, Kerrou K, Younsi N, Wioland M,
Leverger G, Talbot J N.
[(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
Eur J Nucl Med Mol Imaging.
2002;
29
1155-1165
, Epub 2002 Jun 25
- 30
O'Hara S M, Donnelly L F, Coleman R E.
Pediatric body applications of FDG PET.
AJR Am J Roentgenol.
1999;
172
1019-1024
- 31
Shulkin B L.
PET imaging in pediatric oncology.
Pediatr Radiol.
2004;
34
199-204
, Epub 2004 Jan 27
- 32
Shulkin B L, Mitchell D S, Ungar D R, Prakash D, Dole M G, Castle V P, Hernandez R J,
Koeppe R A, Hutchinson R J.
Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
Radiology.
1995;
194
495-500
- 33
Townsend D W, Cherry S R.
Combining anatomy and function: the path to true image fusion.
Eur Radiol.
2001;
11
1968-1974
- 34
Pfluger T, Vollmar C, Porn U, Schmid R, Dresel S, Leinsinger G, Schmid I, Winkler P,
Fischer S, Hahn K.
Combined PET/MRI in cerebral and pediatric diagnostics.
Der Nuklearmediziner.
2002;
25
122-127
- 35
Hueltenschmidt B, Sautter-Bihl M L, Lang O, Maul F D, Fischer J, Mergenthaler H G,
Bihl H.
Whole body positron emission tomography in the treatment of Hodgkin disease.
Cancer.
2001;
91
302-310
- 36
Torabi M, Aquino S L, Harisinghani M G.
Current concepts in lymph node imaging.
J Nucl Med.
2004;
45
1509-1518
- 37
Ilias I, Pacak K.
Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma.
J Clin Endocrinol Metab.
2004;
89
479-491
- 38
Korholz D, Kluge R, Wickmann L, Hirsch W, Luders H, Lotz I, Dannenberg C, Hasenclever D,
Dorffel W, Sabri O.
Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for
staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences
for the GPOH-HD 2003 protocol.
Onkologie.
2003;
26
489-493
- 39
Popperl G, Lang S, Dagdelen O, Jager L, Tiling R, Hahn K, Tatsch K.
Correlation of FDG-PET and MRI/CT with histopathology in primary diagnosis, lymph
node staging and diagnosis of recurrency of head and neck cancer.
Rofo.
2002;
174
714-720
PD Dr. med. T. Pfluger
Klinik und Poliklinik für Nuklearmedizin · Ludwig-Maximilians-Universität München
Ziemssenstraße 1
80336 München
Phone: +49/89/51 60 24 23
Fax: +49/89/51 60 45 55
Email: Thomas.Pfluger@med.uni-muenchen.de
